Before taking Opdualag(Nivolumab and Relatlimab)

This section highlights critical warnings and precautions for safe use of OPDUALAG.

Warnings and Precautions

Key precautions include vigilant monitoring for IMARs, which can occur in any organ system and require prompt management with corticosteroids and/or specialist care. Patients should be closely monitored for signs of infusion-related reactions. Those who undergo allogeneic hematopoietic stem cell transplantation before or after treatment face risks of serious complications, including graft-versus-host disease. Due to embryo-fetal toxicity, females of reproductive potential must use effective contraception during and for at least 5 months after treatment. Patients should be advised not to breastfeed during this period.